Navigation Links
Ansun BioPharma Announces Potent in-vitro DAS181 Activity against Respiratory Syncytial Virus at 5th Congress of Virology
Date:12/8/2015

SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV. "This is very important data as RSV is a common respiratory pathogen and additional treatments are needed," noted Dr. Moss. "As DAS181 is currently in the clinic being studied for the treatment of other respiratory viruses, clinical trials are warranted to test the efficacy of this drug against RSV infection as well," commented Dr. Moss.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  DAS181 has two indications in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. Preclinical data suggests that DAS181 may have additional activity against other respiratory viruses. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

 


'/>"/>
SOURCE Ansun BioPharma
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
4. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
5. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
6. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
7. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
10. Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
11. PDL BioPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):